Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Cash from Financing Activities (2017 - 2025)

Inspire Medical Systems (INSP) has disclosed Cash from Financing Activities for 9 consecutive years, with -$48.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 31.12% to -$48.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$183.4 million through Dec 2025, down 250.14% year-over-year, with the annual reading at -$183.4 million for FY2025, 250.14% down from the prior year.
  • Cash from Financing Activities hit -$48.3 million in Q4 2025 for Inspire Medical Systems, up from -$51.1 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $224.1 million in Q3 2022 to a low of -$87.8 million in Q1 2025.
  • Historically, Cash from Financing Activities has averaged $1.4 million across 5 years, with a median of $3.5 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: surged 5732.03% in 2022 and later tumbled 11527.08% in 2025.
  • Year by year, Cash from Financing Activities stood at $4.1 million in 2021, then soared by 78.83% to $7.3 million in 2022, then plummeted by 238.77% to -$10.1 million in 2023, then plummeted by 593.41% to -$70.1 million in 2024, then surged by 31.12% to -$48.3 million in 2025.
  • Business Quant data shows Cash from Financing Activities for INSP at -$48.3 million in Q4 2025, -$51.1 million in Q3 2025, and $3.7 million in Q2 2025.